HOUSE DOCKET, NO. 1974 FILED ON: 1/17/2013
HOUSE . . . . . . . . . . . . . . . No. 1978
|
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Thomas A. Golden, Jr.
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying resolve:
Resolve relative to responsible prescription prescribing.
_______________
PETITION OF:
Name: | District/Address: | Date Added: |
Thomas A. Golden, Jr. | 16th Middlesex | 1/17/2013 |
Colleen M. Garry | 36th Middlesex |
|
Martin J. Walsh | 13th Suffolk |
|
HOUSE DOCKET, NO. 1974 FILED ON: 1/17/2013
HOUSE . . . . . . . . . . . . . . . No. 1978
By Mr. Golden of Lowell, a petition (accompanied by resolve, House, No. 1978) of Thomas A. Golden, Jr., Colleen M. Garry and Martin J. Walsh for an investigation by a special commission (including members of the General Court) relative to responsible practices in issuing prescriptions. Public Health. |
[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE HOUSE, NO. 3364 OF 2011-2012.]
The Commonwealth of Massachusetts
_______________
In the Year Two Thousand Thirteen
_______________
Resolve relative to responsible prescription prescribing.
Resolved, There is hereby established a special commission to investigate responsible prescription practices in Massachusetts. The commission shall consist of 3 members of the house of representatives, 1 of whom shall be appointed by the minority leader of the house of representatives; 3 members of the senate, 1 of whom shall be appointed by the minority leader of the Senate; 1 representative from the executive office for administration and finance; the commissioner of public health drug control program or the commissioner's designee; the director of the prescription monitoring program or the director's designee; and 3 members appointed by the governor that represent the medical and pharmaceutical community with specialty experience in drug regulation, prescription, treatment and abuse. The commission's investigation, shall include, but not be limited to best practices for responsible prescription. The commission shall submit a report of its findings, including legislative recommendations, if any, to the joint committee on public health and the house and senate committees on ways and means by April 15, 2014.